0000000001276864

AUTHOR

J. Watkins

showing 3 related works from this author

Measurement of the Spectral Shape of the β -Decay of Xe137 to the Ground State of Cs137 in EXO-200 and Comparison with Theory

2020

We report on a comparison between the theoretically predicted and experimentally measured spectra of the first-forbidden nonunique β-decay transition ^{137}Xe(7/2^{-})→^{137}Cs(7/2^{+}). The experimental data were acquired by the EXO-200 experiment during a deployment of an AmBe neutron source. The ultralow background environment of EXO-200, together with dedicated source deployment and analysis procedures, allowed for collection of a pure sample of the decays, with an estimated signal to background ratio of more than 99 to 1 in the energy range from 1075 to 4175 keV. In addition to providing a rare and accurate measurement of the first-forbidden nonunique β-decay shape, this work constitut…

PhysicsSpectral shape analysisGeneral Physics and AstronomyNuclear dataContext (language use)Electron7. Clean energy01 natural sciencesSpectral line0103 physical sciencesNeutron sourceAtomic physics010306 general physicsGround stateEnergy (signal processing)Physical Review Letters
researchProduct

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

2011

INTRODUCTION: Differentiation between steatosis and non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. PATIENTS AND METHODS: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. RESULTS: …

Liver CirrhosisAdultMaleBiopsyHyperlipidemiasFatty Liver/blood/diagnosis/etiology/pathologyRisk AssessmentSeverity of Illness IndexHepatitisBody Mass IndexDiabetes ComplicationsYoung AdultNon-alcoholic Fatty Liver DiseasePredictive Value of TestsRisk FactorsNAFLDLondonMetabolic Syndrome X/blood/*complicationsHumansAspartate AminotransferasesObesityBiological Markers/bloodliver fibrosisAgedMetabolic SyndromeInflammationFerritinChi-Square DistributionPatient SelectionNASHHepatitis/blood/complications/*diagnosisMiddle AgedFibrosisFatty LiverLiver Cirrhosis/blood/*diagnosis/etiologyNomogramsLogistic ModelsHyperlipidemias/blood/complicationsHypertension/blood/complicationsFerritinsHypertensionFerritin; Fibrosis; Inflammation; NAFLD; NASHAspartate Aminotransferases/bloodFemaleDiabetes Complications/blood/diagnosis/etiologyObesity/complicationsBiomarkersFerritins/*blood
researchProduct

Measurement of the Spectral Shape of the beta-decay of 137Xe to the Ground State of 137Cs in EXO-200 and Comparison with Theory

2020

We report on a comparison between the theoretically predicted and experimentally measured spectra of the first-forbidden non-unique $\beta$-decay transition $^{137}\textrm{Xe}(7/2^-)\to\,^{137}\textrm{Cs}(7/2^+)$. The experimental data were acquired by the EXO-200 experiment during a deployment of an AmBe neutron source. The ultra-low background environment of EXO-200, together with dedicated source deployment and analysis procedures, allowed for collection of a pure sample of the decays, with an estimated signal-to-background ratio of more than 99-to-1 in the energy range from 1075 to 4175 keV. In addition to providing a rare and accurate measurement of the first-forbidden non-unique $\bet…

Nuclear Theory (nucl-th)Nuclear TheoryFOS: Physical sciencesNuclear Experiment (nucl-ex)Nuclear Experiment
researchProduct